Phuturdex › Diseases › Infection
Drugs in development · updated 30 October 2026
Infection: drugs in development
As of 30 October 2026 there are 46 active clinical trials (recruiting or ongoing, phases I–III) on 71 drugs for infection. 24 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Ibuzatrelvir | III | 2 | NCT06679140 |
| Fusidic Acid | III | 1 | NCT06911424 |
| GBS-NN | II–III | 1 | NCT06592586 |
| Immunoglobulins | II–III | 1 | NCT05678621 |
| Temocillin | III | 1 | NCT07631364 |
| Tozorakimab | III | 1 | NCT05624450 |
| ACC017 | I–II | 2 | NCT07711223 |
| AHB-137 | II | 2 | NCT07654283 |
| Azithromcyin | II | 1 | NCT07485010 |
| BRII-179 | II | 1 | NCT06650852 |
| BRII-835 | II | 1 | NCT06650852 |
| ChidamideTucidinostat, HBI-8000 | I–II | 1 | NCT07133776 |
| LAD328 | II | 1 | NCT07547813 |
| MRG-001 | II | 1 | NCT06307522 |
| Rhu-pGSN | II | 1 | NCT05947955 |
| TP-05 | II | 1 | NCT07562087 |
| BG505 | I | 1 | NCT05217641 |
| Matrix M | I | 1 | NCT06141057 |
| MRNA-1189 | I | 1 | NCT05831111 |
| MRNA-1195 | I | 1 | NCT05831111 |
| MRNA-1195.1 | I | 1 | NCT05831111 |
| MRNA-1195.2 | I | 1 | NCT05831111 |
| Ohio-99 | I | 1 | NCT07215871 |
| VK-2019 | I | 1 | NCT06789159 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AzithromycinAzasite®, Zithromax® | III | 4 | NCT06605118 |
| Amoxicillinamoxycillin, Moxatag® | II–III | 3 | NCT07202091 |
| SulfamethoxazoleGantanol®, Gantanol-Ds® | II–III | 3 | NCT07202052 |
| TrimethoprimPrimsol®, Trimpex 200® | II–III | 3 | NCT07202052 |
| CeftriaxoneROCEPHIN, Ceftriaxone And Dextrose In Duplex Container® | III | 2 | NCT07631364 |
| Clavulanic acid | II–III | 2 | NCT07202091 |
| EthambutolMyambutol® | III | 2 | NCT06253715 |
| MoxifloxacinIZILOX, Moxeza® | III | 2 | NCT06253715 |
| RifampicinRifampin, RIFADIN | III | 2 | NCT06253715 |
| Amoxi ClavulanateAmoxicillin clavulanic acid, Augmentin | II–III | 1 | NCT07202052 |
| CabotegravirAPRETUDE, Vocabria® | III | 1 | NCT02951052 |
| CephalexinKeftab®, Keflet® | III | 1 | NCT07665476 |
| ChlorhexidineReadyprep Chg®, Periochip® | III | 1 | NCT06489431 |
| CiprofloxacinOtiprio®, Cetraxal® | II–III | 1 | NCT05678621 |
| GentamicinGentamicine, Garamycin® | III | 1 | NCT06489431 |
Sorted by most advanced phase and number of active trials. Showing 15 of 47 drugs.
All 71 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Burkitt lymphoma 113 drugs
- COVID-19 104 drugs
- HIV infection 84 drugs
- Acquired Immunodeficiency Syndrome 61 drugs
- Chronic hepatitis B 42 drugs
- Influenza 68 drugs
- Hidradenitis suppurativa 36 drugs
- Merkel cell carcinoma 48 drugs
- Tuberculosis 48 drugs
- Sepsis 48 drugs
- Post-Acute COVID-19 Syndrome 44 drugs
- Precursor lymphoblastic lymphoma/leukemia 163 drugs
Broader categories
- Immune System Diseases 54 drugs
- Urogenital Diseases 16 drugs
- Genital Diseases 7 drugs
- Virus Diseases 26 drugs
- Respiratory disease 57 drugs
- Hematologic Diseases 57 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D007239 “Infections”.